<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="Multidrug-resistant Salmonella enterica subsp. enterica serovar Typhi (resistant to ampicillin," exact="chloramphenicol" post="and cotrimoxazole), was significantly reduced with the increased usage"/>
 <result pre="led to declining multidrug resistance rates in India with increasing" exact="ciprofloxacin" post="nonsusceptibility rates and clinical failures due to azithromycin. However,"/>
 <result pre="to azithromycin. However, for the available agents such as ceftriaxone," exact="azithromycin" post="and fluoroquinolones, the dose and duration for treatment is"/>
 <result pre="countries and is a major public health concern. Cephalosporins or" exact="azithromycin" post="are the drugs of choice for treating infection caused"/>
 <result pre="endemic areas. This review summarizes the field so far. Keywords: " exact="azithromycin" post="cefixime ceftriaxone Salmonella Typhi Typhoid fever is caused by"/>
 <result pre="areas. This review summarizes the field so far. Keywords:  azithromycin" exact="cefixime" post="ceftriaxone Salmonella Typhi Typhoid fever is caused by the"/>
 <result pre="This review summarizes the field so far. Keywords:  azithromycin cefixime" exact="ceftriaxone" post="Salmonella Typhi Typhoid fever is caused by the bacterium"/>
 <result pre="continued transmission [ 2]. In late 1980s, 2–3 weeks of" exact="chloramphenicol" post="was the treatment of choice for typhoid fever ["/>
 <result pre="number of strains with plasmid-mediated multidrug resistance (MDR) to chloramphenicol," exact="ampicillin" post="and cotrimoxazole are reported. Fluoroquinolone (ciprofloxacin and ofloxacin) has"/>
 <result pre="to cephalosporins, the spread of strains with decreased susceptibility to" exact="ciprofloxacin" post="has limited their effectiveness, particularly in Asia [ 5]."/>
 <result pre="Asia [ 5]. Extended spectrum cephalosporins (ceftriaxone and cefixime) and" exact="azithromycin" post="are suitable alternatives for reduced fluoroquinolone susceptible S. Typhi"/>
 <result pre="S. Typhi [ 2, 6]. The combinations of cephalosporin and" exact="azithromycin" post="are quite frequently used to treat the patients who"/>
 <result pre="hospital for blood cultures. In India, ofloxacin-based combinations such as" exact="ofloxacin" post="plus cefixime or ofloxacin plus azithromycin are most abundantly"/>
 <result pre="blood cultures. In India, ofloxacin-based combinations such as ofloxacin plus" exact="cefixime" post="or ofloxacin plus azithromycin are most abundantly used and"/>
 <result pre="In India, ofloxacin-based combinations such as ofloxacin plus cefixime or" exact="ofloxacin" post="plus azithromycin are most abundantly used and are available"/>
 <result pre="ofloxacin-based combinations such as ofloxacin plus cefixime or ofloxacin plus" exact="azithromycin" post="are most abundantly used and are available over the"/>
 <result pre="the high rates of MDR strains, the use of ampicillin," exact="chloramphenicol" post="and cotrimoxazole has declined, resulting in the increased use"/>
 <result pre="20, 21]. This has resulted in the phenomenon of decreased" exact="ciprofloxacin" post="susceptibility (DCS) while cephalosporin resistance has begun to rise."/>
 <result pre="0–6% †MDR S. Typhi classified based in resistance to ampicillin," exact="chloramphenicol" post="and cotrimoxazole is coming down in the recent years."/>
 <result pre="is coming down in the recent years. ‡High rates of" exact="ciprofloxacin" post="resistance is due to the revised breakpoints in the"/>
 <result pre="are the direct inhibitors of bacterial DNA synthesis. Ciprofloxacin and" exact="ofloxacin" post="are currently the drugs of choice for most cases"/>
 <result pre="of reduced susceptibility to fluoroquinolones has also been implicated in" exact="ofloxacin" post="treatment. For the isolates with an MIC of ≥0.25"/>
 <result pre="the clinical failure cases of S. Typhi when the isolates" exact="ofloxacin" post="MIC was ≥0.25 μg/ml. However, for isolates with an"/>
 <result pre="≤2 μg/ml in 2012 to ≤0.12 μg/ml in 2013 for" exact="ofloxacin" post="and levofloxacin as well [ 38]. For ciprofloxacin, the"/>
 <result pre="in 2012 to ≤0.12 μg/ml in 2013 for ofloxacin and" exact="levofloxacin" post="as well [ 38]. For ciprofloxacin, the CLSI has"/>
 <result pre="[ 39]. Clinically, DCS is associated with clinical failure when" exact="ciprofloxacin" post="MIC was ranging from 0.12 to 1 μg/ml, which"/>
 <result pre="seen in India [ 23, 40]. MDR isolates with decreased" exact="ciprofloxacin" post="susceptibility strains in India are on the increase, and"/>
 <result pre="41]. Earlier, this was missed as the dependence was on" exact="nalidixic acid" post="resistance (NAR) using disc diffusion testing. Moreover, monitoring NAR"/>
 <result pre="diffusion testing. Moreover, monitoring NAR was not carried out with" exact="ciprofloxacin" post="MIC. However, in recent times, rising DCS with the"/>
 <result pre="with a parallel increase in DCS among S. Typhi. Ampicillin," exact="chloramphenicol" post="or cotrimoxazole are less likely preferred because of longer"/>
 <result pre="Studies have reported that plasmid-mediated resistance showed reduced susceptibility to" exact="ciprofloxacin" post="(MIC of 0.125–1.0 μg/ml), which could not be picked"/>
 <result pre="0.125–1.0 μg/ml), which could not be picked up by the" exact="nalidixic acid" post="test [ 43]. Therefore, the CLSI and EUCAST recommend"/>
 <result pre="CLSI and EUCAST recommend a new screening surrogate marker of" exact="pefloxacin" post="(5 μg) disc diffusion for detecting both chromosomal- and"/>
 <result pre="by testing of pefloxacin, wherein 80% of the NAR and" exact="ciprofloxacin" post="moderately susceptible isolates were resistant to pefloxacin [ 44,"/>
 <result pre="the NAR and ciprofloxacin moderately susceptible isolates were resistant to" exact="pefloxacin" post="[ 44, 45]. Therefore, pefloxacin testing would ultimately help"/>
 <result pre="susceptible isolates were resistant to pefloxacin [ 44, 45]. Therefore," exact="pefloxacin" post="testing would ultimately help in the accurate identification of"/>
 <result pre="MIC 50 of 0.19 μg/ml against S. Typhi, compared with" exact="ciprofloxacin" post="and ofloxacin (MIC 50, 0.75 μg/ml) [ 46]. Strikingly,"/>
 <result pre="of 0.19 μg/ml against S. Typhi, compared with ciprofloxacin and" exact="ofloxacin" post="(MIC 50, 0.75 μg/ml) [ 46]. Strikingly, gatifloxacin showed"/>
 <result pre="ciprofloxacin and ofloxacin (MIC 50, 0.75 μg/ml) [ 46]. Strikingly," exact="gatifloxacin" post="showed activity against isolates with DCS phenomenon. This is"/>
 <result pre="with DCS phenomenon. This is due to the ability of" exact="gatifloxacin" post="to evade the point mutations in gyrA (Ser 83"/>
 <result pre="range was observed to be 0.006–0.25 and 0.012–0.19 μg/ml for" exact="ciprofloxacin" post="and gatifloxacin, respectively [ 47]. Furthermore, two trials have"/>
 <result pre="7 days of therapy (10 mg/kg per day) and suggested" exact="gatifloxacin" post="to be more effective than other agents. More importantly,"/>
 <result pre="who received cefixime, with 3.5 and 37.6% treatment failure in" exact="gatifloxacin" post="and cefixime groups, respectively [ 46, 48]. Dysglycemia is"/>
 <result pre="cefixime, with 3.5 and 37.6% treatment failure in gatifloxacin and" exact="cefixime" post="groups, respectively [ 46, 48]. Dysglycemia is a major"/>
 <result pre="concern, for which sugar monitoring is essential [ 49]. Although" exact="gatifloxacin" post="has an advantage over other quinolones, its use is"/>
 <result pre="death. With the rising DCS phenomenon, third-generation cephalosporins such as" exact="cefixime" post="and ceftriaxone are preferred for the treatment of MDR"/>
 <result pre="the rising DCS phenomenon, third-generation cephalosporins such as cefixime and" exact="ceftriaxone" post="are preferred for the treatment of MDR and nalidixic"/>
 <result pre="trials assessment in Asia showed that the resistance prevalence to" exact="ceftriaxone" post="was 0%, with cure rate of 72–97% with 3–14"/>
 <result pre="any relapses [ 54]. Although the route of administration of" exact="ceftriaxone" post="is parental, it requires hospitalization and increase in healthcare"/>
 <result pre="for treating mild-to-moderate enteric fever. Clearly defined MIC breakpoints for" exact="azithromycin" post="susceptibility have not been established, but data suggest that"/>
 <result pre="isolates with an MIC ≤16 μg/ml generally respond well to" exact="azithromycin" post="and can be considered susceptible. The available clinical or"/>
 <result pre="considered susceptible. The available clinical or pharmacokinetic/pharmacodynamic (PK/PD) data on" exact="azithromycin" post="are limited. Notably, azithromycin nonsusceptibility rate was lower than"/>
 <result pre="clinical or pharmacokinetic/pharmacodynamic (PK/PD) data on azithromycin are limited. Notably," exact="azithromycin" post="nonsusceptibility rate was lower than the other agents. In"/>
 <result pre="trials has proven that the relapse rate was 0% with" exact="azithromycin" post="treatment, while the cure rate was about 81–100% with"/>
 <result pre="μg/ml [ 40]. Following this, 34 and 38% resistance to" exact="azithromycin" post="was reported in S. Typhi and S. Paratyphi A,"/>
 <result pre="S. Paratyphi A, respectively [ 55]. Recently, a case of" exact="azithromycin" post="clinical and microbiological failure with the MIC of 4"/>
 <result pre="infection, from India [ 56]. Similarly, S. Paratyphi A with" exact="azithromycin" post="clinical failure case with MIC of 12 μg/ml was"/>
 <result pre="5–7 days of therapy for complete cure [ 58]. However," exact="azithromycin" post="is not preferred as a monotherapy in severe typhoid,"/>
 <result pre="results in poor clinical response. Moreover, determination of MIC for" exact="azithromycin" post="and monitoring clinical success is essential. Typhoid fever therapy:"/>
 <result pre="rise in nalidixic acid-resistant S. Typhi (NARST) and cases of" exact="azithromycin" post="treatment failure are of concern [ 37, 56]. Typically,"/>
 <result pre="settings contributes to emergence of strains with elevated MIC to" exact="ciprofloxacin" post="and ofloxacin across Asia and parts of Africa ["/>
 <result pre="to emergence of strains with elevated MIC to ciprofloxacin and" exact="ofloxacin" post="across Asia and parts of Africa [ 63, 64]."/>
 <result pre="days 1–2 g per day IV; for 7–10 days Ciprofloxacin," exact="levofloxacin" post="or other FQ † Oral/IV – FQ given in"/>
 <result pre="of 22 different Indian brands of fixed-dose combinations (FDCs) containing" exact="azithromycin" post="with ofloxacin or cefixime revealed that while formulations contained"/>
 <result pre="different Indian brands of fixed-dose combinations (FDCs) containing azithromycin with" exact="ofloxacin" post="or cefixime revealed that while formulations contained an adequate"/>
 <result pre="brands of fixed-dose combinations (FDCs) containing azithromycin with ofloxacin or" exact="cefixime" post="revealed that while formulations contained an adequate fluoroquinolone or"/>
 <result pre="contained an adequate fluoroquinolone or cephalosporin dose, the dose of" exact="azithromycin" post="was 250 mg/tablet. This quantity is one fifth of"/>
 <result pre="determined. A randomized controlled trial by Parry et al. comparing" exact="ofloxacin" post="(20 mg/kg body weight per day for 7 days),"/>
 <result pre="ofloxacin (20 mg/kg body weight per day for 7 days)," exact="azithromycin" post="(10 mg/kg per day for 7 days) and ofloxacin"/>
 <result pre="days), azithromycin (10 mg/kg per day for 7 days) and" exact="ofloxacin" post="(15 mg/kg per day for 7 days) combined with"/>
 <result pre="ofloxacin (15 mg/kg per day for 7 days) combined with" exact="azithromycin" post="(10 mg/kg per day for the first 3 days)"/>
 <result pre="significantly shorter than that for patients treated with ofloxacin–azithromycin and" exact="ofloxacin" post="alone. Table 4 summarizes the studies on monotherapy and"/>
 <result pre="failure (%) Relapse (%) Fecal carriage (%) Ref. Azithromycin vs" exact="ceftriaxone" post="(IV; short course therapy) 108 (children) Prospective study (2000)/Egypt"/>
 <result pre="– 0 Ceftriaxone – 13 NA [ 65] Azithromycin vs" exact="ceftriaxone" post="(IV; short course therapy) 149 Prospective study (2004)/Egypt Azithromycin"/>
 <result pre="failure: Azithromycin – 15.5 NA NA [ 67] Azithromycin vs" exact="ofloxacin" post="40 (adult) Prospective (2012)/India Ofloxacin – 200 mg orally"/>
 <result pre="Azithromycin – 0 No relapse 0 [ 68] Ofloxacin vs" exact="cefixime" post="82 (children) Randomized open trial (1995–1996)/Vietnam Ofloxacin – 10"/>
 <result pre="group: 2 3-day group: 2 NA [ 70] Chloramphenicol vs" exact="ofloxacin" post="50 Randomized open study/Laos Chloramphenicol (50 mg/kg per day)"/>
 <result pre="failure: Chloramphenicol – 1% NA NA [ 71] Ofloxacin vs" exact="azithromycin" post="88 Randomized control study/Nepal Azithromycin (20 mg/kg per day)"/>
 <result pre="microbiologcal failure) Relapse was not seen in patients treated with" exact="ofloxacin" post="or azithromycin or ofloxacin/azithromycin Ofloxacin – 19.4 Azithromycin –"/>
 <result pre="Relapse was not seen in patients treated with ofloxacin or" exact="azithromycin" post="or ofloxacin/azithromycin Ofloxacin – 19.4 Azithromycin – 1.6 Ofloxacin/azithromycin"/>
 <result pre="Azithromycin – 1.6 Ofloxacin/azithromycin – 6.5 [ 73] Gatifloxacin vs" exact="azithromycin" post="287 RCT/Vietnam Gatifloxacin (10 mg/kg per day) for 7"/>
 <result pre="Gatifloxacin – 0.7 Azithromycin – 0 [ 46] Gatifloxacin vs" exact="cefixime" post="390 RCT/Nepal Gatifloxacin (10 mg/kg per day) for 7"/>
 <result pre="– 0.9 Cefixime – 3 NA [ 48] Gatifloxacin vs" exact="chloramphenicol" post="844 RCT/Nepal Gatifloxacin (10 mg/kg per day) for 7"/>
 <result pre="– 2 Chloramphenicol – 4 NA [ 74] Gatifloxacin vs" exact="ofloxacin" post="627 RCT/Nepal Gatifloxacin (10 mg/kg per day) for 7"/>
 <result pre="– 5 Ofloxacin – 6 NA [ 75] Gatifloxacin vs" exact="ceftriaxone" post="239 RCT/Nepal Gatifloxacin (10 mg/kg per day) for 7"/>
 <result pre="Intravenous; NA: Not available; RCT: Randomized clinical trial. Fluoroquinolones and" exact="azithromycin" post="attain better tissue penetration and kill bacteria within monocytes/macrophages"/>
 <result pre="treated with ceftriaxone–azithromycin combination therapy compared with those treated with" exact="ceftriaxone" post="monotherapy [ 78]. However, the significance of this finding"/>
 <result pre="[ 52, 56, 81]. However, antimicrobial resistance to ceftriaxone/cefixime and" exact="azithromycin" post="remains rare. In the areas where fluoroquinolone resistance is"/>
 <result pre="rise and therefore the drug of choice is limited to" exact="azithromycin" post="or cephalosporins, which are expensive. Randomized control trials (RCTs)"/>
 <result pre="48, 65, 69, 76]. Similarly, RCTs on treating uncomplicated with" exact="azithromycin" post="for 5–7 days resulted in 95% cure rate and"/>
 <result pre="The complimentary action of cephalosporins on the extracellular compartment and" exact="azithromycin" post="on the intracellular compartment could be beneficial in treating"/>
 <result pre="include cefixime–azithromycin, cefpodoxime–azithromycin and ofloxacin–azithromycin. Azithromycin is known to reduce" exact="cefpodoxime" post="efficacy by PD antagonism [ 85]. The expert committee"/>
 <result pre="are in progress. In the differential diagnosis of febrile illness," exact="doxycycline" post="plus cefixime–azithromycin is prescribed as empiric therapy, especially in"/>
 <result pre="where rickettsial infection is common. However, drug–drug interactions showed that" exact="doxycycline" post="decreases effects of ceftriaxone by PD antagonism [ 85]."/>
 <result pre="common. However, drug–drug interactions showed that doxycycline decreases effects of" exact="ceftriaxone" post="by PD antagonism [ 85]. There is a huge"/>
 <result pre="86]. An in vitro study has demonstrated significant synergy of" exact="chloramphenicol" post="and trimethoprim with O. sanctum leaf extract against S."/>
 <result pre="in vitro study has demonstrated significant synergy of chloramphenicol and" exact="trimethoprim" post="with O. sanctum leaf extract against S. Typhi ["/>
 <result pre="fever remain uncertain. Conclusion Given the emergence of fluoroquinolone and" exact="azithromycin" post="nonsusceptible S. Typhi strains, it is interesting to note"/>
 <result pre="in India. This observation suggests the possible reintroduction of ampicillin," exact="chloramphenicol" post="and cotrimoxazole as first-line options. While these agents are"/>
 <result pre="into routine first-line use. In severe cases of typhoid fever," exact="ceftriaxone" post="IV (2 g per day) for 10–14 days is"/>
 <result pre="g per day) for 10–14 days is given followed by" exact="azithromycin" post="(20 mg/kg per day) for 7 days. For DCS"/>
 <result pre="therapy is to be avoided. If necessary, higher dose of" exact="ciprofloxacin" post="(20 mg/kg per day) may be more effective in"/>
 <result pre="relapse and faecal carriage can be expected. Therefore, treatment with" exact="azithromycin" post="(20 mg/kg per day) for 7 days is recommended"/>
 <result pre="treating uncomplicated cases. Future perspective Increased use of cephalosporin or" exact="azithromycin" post="in treating fluoroquinolone nonsusceptible S. Typhi may lead to"/>
 <result pre="Typhi may lead to a rise in cephalosporin resistance or" exact="azithromycin" post="treatment failure. In the era of MDR, combination therapy"/>
 <result pre="significant concern in developing countries. Third-generation cephalosporins (cefixime, ceftriaxone) or" exact="azithromycin" post="are the alternative for treating S. Typhi infection with"/>
 <result pre="with decreased susceptibility to ciprofloxacin. An approach of cephalosporin plus" exact="azithromycin" post="can address the shortcomings of cephalosporins including poor response"/>
 <result pre="Maksoud MA et al. Multi-drug resistance and reduced susceptibility to" exact="ciprofloxacin" post="among Salmonella enterica serovar Typhi isolates from the Middle"/>
 <result pre="20 Balaji V Sharma A Ranjan P et al. Revised" exact="ciprofloxacin" post="breakpoints for Salmonella Typhi: its implications in India Indian"/>
 <result pre="Raveendran R Wattal C Sharma A et al. High level" exact="ciprofloxacin" post="resistance in Salmonella enterica isolated from blood Indian J."/>
 <result pre="Antibiogram of Salmonella isolates from blood with an emphasis on" exact="nalidixic acid" post="and chloramphenicol susceptibility in a tertiary care hospital in"/>
 <result pre="isolates from blood with an emphasis on nalidixic acid and" exact="chloramphenicol" post="susceptibility in a tertiary care hospital in coastal Karnataka:"/>
 <result pre="M Joyce K Blickenstaff K et al. Antimicrobial susceptibility to" exact="azithromycin" post="among Salmonella enterica isolates from the United States Antimicrob."/>
 <result pre="DB Day NPJ Nguyen MD Pharmacokinetics of oral and intravenous" exact="ofloxacin" post="in multidrug-resistant typhoid fever Antimicrob. Agents Chemother. 40 2167"/>
 <result pre="in Salmonella enterica serovar Typhi on the clinical response to" exact="ofloxacin" post="therapy PLoS Negl. Trop. Dis. 5 6 e1163 2011"/>
 <result pre="molecular analysis of strains with decreased susceptibility and resistant to" exact="ciprofloxacin" post="in India from 2001–2003 Braz. J. Infect. Dis. 11"/>
 <result pre="18258138 •• Describes the plasmid-mediated quinolone-resistant gene distribution among reduced" exact="ciprofloxacin" post="susceptible S. Typhi. 43 Balaji V Shalini A Dhiviya"/>
 <result pre="et al. Molecular characterization of intermediate susceptible Typhoidal Salmonella to" exact="ciprofloxacin" post="and its impact Mol. Diagn. Ther. 20 3 213"/>
 <result pre="213 219 2016 26951258 • Describes the advantage of using" exact="pefloxacin" post="for screening of reduced fluoroquinolone susceptible S. Typhi. 44"/>
 <result pre="Nguyen NR et al. A multi-center randomised controlled trial of" exact="gatifloxacin" post="versus azithromycin for the treatment of uncomplicated typhoid fever"/>
 <result pre="et al. A multi-center randomised controlled trial of gatifloxacin versus" exact="azithromycin" post="for the treatment of uncomplicated typhoid fever in children"/>
 <result pre="A Day JN et al. An open randomized comparison of" exact="gatifloxacin" post="versus cefixime for the treatment of uncomplicated enteric fever"/>
 <result pre="JN et al. An open randomized comparison of gatifloxacin versus" exact="cefixime" post="for the treatment of uncomplicated enteric fever PLoS ONE"/>
 <result pre="Rai S Jain S Prasad KN et al. Rationale of" exact="azithromycin" post="prescribing practices for enteric fever in India Indian J."/>
 <result pre="1 30 33 2012 22361757 • Describes the case of" exact="azithromycin" post="treatment failure. 56 Manesh A Balaji V Kumar DRN"/>
 <result pre="et al. A case of clinical and microbiological failure of" exact="azithromycin" post="therapy in Salmonella enterica serotype Typhi despite low azithromycin"/>
 <result pre="of azithromycin therapy in Salmonella enterica serotype Typhi despite low" exact="azithromycin" post="MIC Int. J. Infect. Dis. 54 62 63 2017"/>
 <result pre="Thieu NT Dolecek C et al. Clinically and microbiologically derived" exact="azithromycin" post="susceptibility breakpoints for Salmonella enterica serovars Typhi and Paratyphi"/>
 <result pre="60 Hassing RJ Goessens WH Mevius DJ et al. Decreased" exact="ciprofloxacin" post="susceptibility in Salmonella Typhi and Paratyphi infections in ill-returned"/>
 <result pre="Koirala S Basnyat B Arjyal A et al. Gatifloxacin versus" exact="ofloxacin" post="for the treatment of uncomplicated enteric fever in Nepal:"/>
 <result pre="Frenck RW Nakhla I Sultan Y et al. Azithromycin versus" exact="ceftriaxone" post="for the treatment of uncomplicated typhoid fever in children"/>
 <result pre="66 Frenck RW Mansour A Nakhla I et al. Short-course" exact="azithromycin" post="for the treatment of uncomplicated typhoid fever in children"/>
 <result pre="Ghosh A Gomber S et al. Efficacy and safety of" exact="azithromycin" post="for uncomplicated typhoid fever: an open label non-comparative study"/>
 <result pre="Multani AS A comparative study of efficacy and safety of" exact="azithromycin" post="and ofloxacin in uncomplicated typhoid fever: a randomised, open"/>
 <result pre="A comparative study of efficacy and safety of azithromycin and" exact="ofloxacin" post="in uncomplicated typhoid fever: a randomised, open labelled study"/>
 <result pre="Kneen R Nguyen TA et al. A comparative study of" exact="ofloxacin" post="and cefixime for treatment of typhoid fever in children."/>
 <result pre="Nguyen TA et al. A comparative study of ofloxacin and" exact="cefixime" post="for treatment of typhoid fever in children. The Dong"/>
 <result pre="Duong NM Phuong LT et al. Comparative trial of short-course" exact="ofloxacin" post="for uncomplicated typhoid fever in Vietnamese children Ann. Trop."/>
 <result pre="R Sisouphone S et al. A randomized comparison of oral" exact="chloramphenicol" post="versus ofloxacin in the treatment of uncomplicated typhoid fever"/>
 <result pre="S et al. A randomized comparison of oral chloramphenicol versus" exact="ofloxacin" post="in the treatment of uncomplicated typhoid fever in Laos"/>
 <result pre="CM Ly NT et al. A randomized controlled comparison of" exact="azithromycin" post="and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant"/>
 <result pre="NT et al. A randomized controlled comparison of azithromycin and" exact="ofloxacin" post="for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever"/>
 <result pre="Arjyal A Basnyat B Koirala S et al. Gatifloxacin versus" exact="chloramphenicol" post="for uncomplicated enteric fever: an open-label, randomised, controlled trial"/>
 <result pre="Koirala S Basnyat B Arjyal A et al. Gatifloxacin versus" exact="ofloxacin" post="for the treatment of uncomplicated enteric fever in Nepal:"/>
 <result pre="Arjyal A Basnyat B Nhan HT et al. Gatifloxacin versus" exact="ceftriaxone" post="for uncomplicated enteric fever in Nepal: an open-label, two-centre,"/>
 <result pre="2015 www.medicines-complete.com 86 Mandal S Mandal MD Pal NK Enhancing" exact="chloramphenicol" post="and trimethoprim in vitro activity by Ocimum sanctum Linn."/>
 <result pre="86 Mandal S Mandal MD Pal NK Enhancing chloramphenicol and" exact="trimethoprim" post="in vitro activity by Ocimum sanctum Linn. (Lamiaceae) leaf"/>
</results>
